Vaccines
7 November 2013
Agenus’ HerpV Therapeutic Vaccine for Genital Herpes Meets Primary Endpoint in Randomized Phase 2 Trial31 October 2013
GREER® Laboratories, Inc. and STALLERGENES Sign Exclusive Agreement for United States Commercialization Rights to Oralair®31 October 2013
Valneva provides update on the Phase II/III interim analysis of its Pseudomonas aeruginosa vaccine candidate29 October 2013
ISA Pharmaceuticals Initiates Phase I/II Clinical Trial With ISA101 in Women with Cervical Cancer28 October 2013
Stellar Biotechnologies Presents Preclinical Poster on Clostridium Difficile Active Immunotherapy at Vaccine Congress24 October 2013
Merck Provides Update on Investigational 9-valent HPV Vaccine V503 to U.S. Advisory Committee on Immunization Practices21 October 2013
Immunology Data Further Underline the Positive Outcome of a Phase IIb Trial of Anergis’ Birch Pollen Allergy Vaccine AllerT21 October 2013
Inovio Pharmaceuticals Therapeutic Vaccine for Hepatitis C Enters Phase I Clinical Trial15 October 2013
immatics Closes €34 Million Financing to Complete Phase 3 Development of IMA901 for Renal Cancer10 October 2013
S-TARget Achieves Clinical Proof of Concept for Allergy Vaccine SG100 in Asthmatic Non-human Primates9 October 2013
Japanese encephalitis vaccine achieves WHO prequalification, a key step in expanding access and protecting more children8 October 2013
Novavax Initiates Dose-Confirmatory Phase 2 Clinical Trial of its RSV Vaccine Candidate4 October 2013
Takeda Highlights Data from Clinical Trial of Investigational Norovirus Vaccine CandidateNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports